Chronic exercise improves endothelial calcium signaling and vasodilatation in hypercholesterolemic rabbit femoral artery.
OBJECTIVE
This study was to investigate the effects of chronic exercise on vasodilatation and endothelial intracellular calcium (EC [Ca2+]i) signaling in atherosclerotic animals.


RESULTS
For 8 weeks, male New Zealand White rabbits were fed rabbit chow with or without the addition of 2% cholesterol. They were further divided into control and exercise groups. Animals in the exercise groups ran on a leveled treadmill at 0.88 km/h for 10 to 60 minutes gradually for 5 days per week for a total of 8 weeks. At the end of experiments, femoral arteries were dissected, loaded with fura 2-AM, and mounted in a tissue flow chamber. PE-precontracted vessel specimens were exposed to acetylcholine (ACh). The EC [Ca2+]i elevation and vasorelaxation were determined simultaneously under an epifluorescence microscope equipped with a ratio-imaging capability. Our results showed the following: (1) high cholesterol diet feeding caused lipid deposition on vascular surface, reduced the ACh-evoked EC [Ca2+]i elevation, and impaired endothelium-dependent and endothelium-independent vascular responses, but chronic exercise had the opposite effects; (2) ACh-induced vasorelaxation was associated with EC [Ca2+]i elevation in all groups; and (3) vasorelaxation at high levels of EC [Ca2+]i elevation decreased in hypercholesterolemia.


CONCLUSIONS
Our data suggest that hypercholesterolemia induces vascular structural changes and impairs EC [Ca2+]i signaling and vasodilatation, whereas chronic exercise partially reverses these adverse effects.
Jen
Chauying J
CJ
Department of Physiology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Chan
Hung-Pin
HP
Chen
Hsiun-ing
HI
D000109:Acetylcholine / Q000494:pharmacology; D000818:Animals; D001161:Arteriosclerosis / Q000097:blood / Q000503:physiopathology; D001391:Azo Compounds / Q000378:metabolism; D000001:Calcimycin / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D020013:Calcium Signaling / Q000187:drug effects / Q000502:physiology*; D002950:Citrate (si)-Synthase / Q000378:metabolism; D004396:Coloring Agents / Q000378:metabolism; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology*; D005263:Femoral Artery / Q000187:drug effects / Q000503:physiopathology*; D006937:Hypercholesterolemia / Q000097:blood / Q000503:physiopathology*; D066298:In Vitro Techniques; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D018482:Muscle, Skeletal / Q000098:blood supply / Q000187:drug effects / Q000201:enzymology; D009599:Nitroprusside / Q000494:pharmacology; D010656:Phenylephrine / Q000494:pharmacology; D010805:Physical Conditioning, Animal / Q000379:methods / Q000502:physiology*; D011817:Rabbits; D017539:Tunica Intima / Q000737:chemistry / Q000187:drug effects / Q000473:pathology; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology*; D014665:Vasodilator Agents / Q000494:pharmacology
D001391:Azo Compounds; D004396:Coloring Agents; D008055:Lipids; D014665:Vasodilator Agents; D009599:Nitroprusside; D010656:Phenylephrine; D000001:Calcimycin; D002950:Citrate (si)-Synthase; C011049:oil red O; D000109:Acetylcholine; D002118:Calcium